Gilead Sciences's new hepatitis C treatment, Sovaldi, had $3.48 billion in second-quarter sales, more than expected, continuing its historic drug launch.
WSJ.com: US Business, Wall Street Journal: Business
Wed, 07/23/2014 - 5:00pm
Gilead Sciences's new hepatitis C treatment, Sovaldi, had $3.48 billion in second-quarter sales, more than expected, continuing its historic drug launch.